Skin treatment made from stem cell exosomes for diabetic foot
Tests a stem cell-based skin drug for safety and effect in diabetic foot.
Key facts
- Who runs it
- Second Affiliated Hospital of Guangzhou Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Stem Cell Derived Exome for Treatment of Diabetic Foot
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 50 people, planned
- Started
- 1 Aug 2024
- Expected to end
- 30 Dec 2033
- Type of study
- Interventional
- Treatments tested
- Skin drug prepared with exome originated from stem cell
- Record updated
- 28 June 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetic foot. It tests a skin drug made from stem cell derived exome for safety and effect.
- Age
- 18 to 90 years
- Sex
- All sexes
- Disease stage
- Clinical diagnosis of diabetic foot. ECOG score < 4, which means people who are not fully bedbound. Blood clotting must be tolerable or any clotting problem must be reversible.
- Earlier treatment
- People who took part in a trial of a device or drug in the last 4 weeks cannot join.
- Biomarker or test result
- Blood tests within 7 days before the procedure: WBC≥3.0×10E9/L; Hb≥90g/L; PLT ≥50×10E9/L; INR < 2.3 or PT < 6 seconds above control; Cr ≤ 145.5 umul/L; Albumin > 28 g/L; Total bilirubin < 51 μmol/L.
Main reasons for not taking part
- Fluid in the belly (ascites), brain problems from liver disease, or bleeding from swollen veins in the food pipe or stomach
- Serious other illness, such as heart disease, poorly controlled diabetes or psychiatric disorders
- Allergy to the skin drug
- Taking medicines that could change how the study drug is absorbed or handled by the body
- Being unlikely to follow the trial plan
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Clinical diagnosis of diabetic foot
- Signed informed consent before recruiting
- Age above 18 years or less than 90 years
- ECOG score < 4
- Tolerable coagulation function or reversible coagulation disorders
- Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L; PLT ≥50×10E9/L;INR < 2.3 or PT < 6 seconds above control;Cr ≤ 145.5 umul/L;Albumin > 28 g/L;Total bilirubin < 51 μmol/L
- Willing and able to comply with scheduled visits, treatment plan and laboratory tests
Who cannot take part
- Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks
- Any agents which could affect the absorption or pharmacokinetics of the study drugs
- Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding
- Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders
- Allergic to the skin drug
- Other conditions that investigator decides not suitable for the trial
- Patients have poor compliance
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This trial is designed to investigate the safety and efficacy of patients with diabetic foot by using stem cell derived exome.
The group in the trial
- Stem Cell Derived ExomeTreatment being tested
Treatment: Skin drug prepared with exome originated from stem cell
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Skin Drug Prepared From Stem Cell Derived Exome for Treatment of Diabetic Foot: a Phase II Clinical Trial
- Plain-language title
- Skin treatment made from stem cell exosomes for diabetic footGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06480123, who can take part
- Record updated
- 28 June 2024